In-house analytical result, not an independent third-party test
Lot / batch number
PL-2609-031
Date made
2026-09-18
Date of analysis
2026-09-19
Date issued
2026-10-03
Retest / expiry
2028-09-18
Units in lot / sampled
250 / 2
Storage
2–8 °C, dark; do not freeze
Certificate type
Lot COA, 2 pages
Compound
Erythropoietin (rhEPO)
Recombinant human erythropoietin, epoetin class
CAS number
11096-26-7
Molecular formula
C809H1301N229O240S5 (165-residue protein core)
Theoretical mass (avg.)
About 30.4 kDa glycoform average; 18.2 kDa protein core
Structure
165-residue mature human EPO (UniProt P01588 residues 28–192; C-terminal Arg166 removed), CHO-expressed; N-glycans at Asn24, Asn38 and Asn83, O-glycan at Ser126; disulfides Cys7–Cys161 and Cys29–Cys33.
Purity · RP-HPLC, area %
99.18%
Specification 99.0% • main peak (glycoform cluster) at 7.18 min
Identity · Observed Mass
30,412 Da
Deconvoluted glycoform centroid • theoretical 30.4 kDa average
Overall conclusion
PASS
Meets every specification for the tests performed
Test
Method
Specification
Result
Conclusion
Appearance
Visual inspection
White lyophilized powder or cake
White lyophilized cake
PASS
Identity (mass)
LC-MS, ESI positive
Within glycoform envelope
30,412 Da centroid (CHO glycoforms 28–34 kDa)
PASS
Purity
RP-HPLC, UV 214 nm, area%
99.0%
99.18%
PASS
Largest impurity
RP-HPLC, area%
1.0%
0.42% at 6.44 min
PASS
Water content
Karl Fischer
5.0%
1.9%
PASS
Bacterial endotoxin
LAL, kinetic
≤ 5.0 EU/mg
0.27 EU/mg
PASS
Sterility / bioburden
USP <71>, membrane filtration
No growth after 14 days
No growth; conforms
PASS
1HPLC chromatogram
Data file: EPO_PL-2609-031_20260919_01 · Column C18, 150 × 4.6 mm · UV 214 nm
Baseline uncropped; main peak (intact monomer glycoform cluster) and impurities labeled with retention times. Peak table on page 2.
PrymaLab
Certificate of Analysis · continued
EPO (Erythropoietin) 3,000 IU · Lot PL-2609-031 · Certificate PL-26-00031
Lot PL-2609-031
Method, peak table and approval
2HPLC method · EPO_PL-2609-031_20260919_01
Instrument
Waters Alliance e2695, SN E2695B742
Data System
Empower 3, Build 3471
Detector
Waters 2998 PDA
Detection Wavelength
214 nm
Column
C18, 150 × 4.6 mm, 3.5 µm
Column Part / Serial
186003326 / USHX18211
Mobile Phase A
0.1% TFA in water
Mobile Phase B
0.1% TFA in MeCN
Flow Rate
1.0 mL/min
Column Temperature
30 °C
Injection Volume
20 µL
Run Time
10 min
Sample Diluent
Water, 0.1% TFA
Sample Concentration
0.2 mg/mL (pooled composite)
Blank Injected
Yes
Reference Standard
In-house rhEPO reference, lot PL-RS-EPO-01, RT 7.16 min (glycoform cluster)
3Gradient program
Time (min)
% A
% B
0.0
95
5
3.0
95
5
7.0
55
45
8.0
20
80
9.0
20
80
10.0
95
5
4Peak table
Peak
RT (min)
Area
Area %
1
6.44
18,060
0.42
2
7.18
4,264,740
99.18
3
7.74
10,750
0.25
4
8.32
6,450
0.15
Total
4,300,000
100.00
Threshold 0.05% area · Blank subtracted: Y · Purity = main peak area ÷ total integrated area × 100, to two decimals; main peak shaded.
5Identity by mass spectrometry
Instrument
Waters Acquity SQD
Ionization / Mode
ESI, positive
Observed m/z (charge)
1521.6 (20+ [M+20H]) · 1217.5 (25+ [M+25H])
Deconvoluted Mass
30,412 Da (glycoform centroid)
Theoretical Mass
30,400 Da average glycoform (18.2 kDa protein core)
Difference
Within CHO glycoform envelope (28–34 kDa)
Data File
EPO_PL-2609-031_MS_20260919_01
Acceptance
Within glycoform envelope
6Additional tests
Test
Performed by
Date
Report / file
Water content
PrymaLab
2026-09-20
RPT-KF-PL-2609-031
Endotoxin
PrymaLab
2026-09-21
RPT-ET-PL-2609-031
Sterility
PrymaLab
2026-10-02
RPT-ST-PL-2609-031
A test with no row here was not performed on this lot. Outside-laboratory reports, when used, are attached and named below.
7Review and approval
D. Reynolds Analyst · performed the testing Date: 2026-09-19
S. Calloway Reviewer · checked against raw data Date: 2026-10-02
M. Phelps Lab Director · approved for release Date: 2026-10-03